

Appn. Number 10/717,162 (Sung et al.)

GAU 1614

Amnt. A contd.

3 of 7

**RECEIVED  
CENTRAL FAX CENTER****AMENDMENTS TO THE CLAIMS:****OCT 10 2007**

Please cancel claims 5-6, 10 and 21-41 from further consideration. Please amend claims 2-3, 7-8, and 11-18.

A complete listing of all claims and their current status is presented below.

1(original). A medical device, comprising:

a biodegradable apparatus having a surface;  
at least one bioactive agent; and

biological material loaded onto at least a portion of the surface of said apparatus, said biological material comprising said at least one bioactive agent, wherein said biological material is crosslinked with a crosslinking agent or with ultraviolet irradiation.

2(currently amended). The device of claim 1, wherein the crosslinking agent is genipin, its analog, derivatives, and combination thereof.

3(currently amended). The device of claim 1, wherein the crosslinking agent is selected from a group consisting of formaldehyde, glutaraldehyde, dialdehyde starch, glyceraldehydes, cyanamide, diimides, diisocyanates, dimethyl adipimidate, carbodiimide, comprises an epoxy compound, and mixture thereof.

4(original). The device of claim 1, wherein the apparatus is a stent.

5-6(cancelled).

7(currently amended). The device of claim 1, wherein the biological material is selected from a group consisting of collagen, gelatin, elastin, chitosan, N, O-carboxymethyl chitosan, and mixture thereof.

Appn. Number 10/717,162 (Sung et al.) GAU 1614 Amnt. A contd. 4 of 7

8(currently amended). The device of claim 1, wherein the biological material is a solidifiable substrate, and wherein the biological material is solidifiable from a phase selected from a group consisting of solution, paste, gel, suspension, colloid, and plasma.

9(original). The device of claim 1, wherein the biodegradable apparatus is made of a material selected from a group consisting of polylactic acid (PLA), polyglycolic acid (PGA), poly (D,L-lactide-co-glycolide), polycaprolactone, and co-polymers thereof.

10(cancelled).

11(currently amended). The device of claim 1 or 10, wherein the at least one bioactive agent is selected from a group consisting of analgesics/antipyretics, antiasthamatics, antibiotics, antidepressants, antidiabetics, antifungal agents, antihypertensive agents, anti-inflammatories, antineoplastics, antianxiety agents, immunosuppressive agents, antimigraine agents, sedatives/hypnotics, antipsychotic agents, antimanic agents, antiarrhythmics, antiarthritic agents, antigout agents, anticoagulants, thrombolytic agents, antifibrinolytic agents, antiplatelet agents and antibacterial agents, antiviral agents, antimicrobials, and anti-infectives for treating pain or lowering body temperature from a raised state.

12(currently amended). The device of claim 1 or 10, wherein the at least one bioactive agent is selected from a group consisting of actinomycin D, paclitaxel, vincristin, methotrexate, and angiopoetin, batimastat, halofuginone, sirolimus, tacrolimus, everolimus, tranilast, dexamethasone, and mycophenolic acid for treating atherosclerotic plaque.

13(currently amended). The device of claim 1 or 10, wherein the at least one bioactive agent comprises is selected from a group consisting of lovastatin, thromboxane A<sub>2</sub> synthetase inhibitors, eicosapentanoic acid, ciprestene, trapidil, angiotensin converting enzyme inhibitors, aspirin, and heparin for lowering cholesterol in a patient with hypercholesterolemia.

Appn. Number 10/717,162 (Sung et al.) GAU 1614 Amnt. A contd. 5 of 7

14(currently amended). The device of claim 1 or 10, wherein the at least one bioactive agent comprises is selected from a group consisting of alliein, ginseng extract, flavone, ginkgo biloba extract, glycyrrhetic acid, and proanthocyanides for treatment of peptic ulcer.

15(currently amended). The device of claim 1 or 10, wherein the at least one bioactive agent comprises ApoA-I Milano or recombinant ApoA-I Milano/phospholipid complexes for treating atherosclerotic plaque.

16(currently amended). The device of claim 1 or 10, wherein the at least one bioactive agent comprises biological cells for inducing cell proliferation.

17(currently amended). The device of claim 1 or 10, wherein the at least one bioactive agent comprises lipostabil for fat removal from a patient.

18(currently amended). The device of claim 1 or 10, wherein the at least one bioactive agent comprises a growth factor for stimulating cellular proliferation and cellular differentiation.

19(original). The device of claim 18, wherein the growth factor is selected from a group consisting of vascular endothelial growth factor, transforming growth factor-beta, insulin-like growth factor, platelet derived growth factor, fibroblast growth factor, and combination thereof.

20(original). The device of claim 1 further comprising a biodegradable polymer loaded onto at least a portion of the surface of said apparatus.

20(cancelled). A biodegradable medical device comprising at least one bioactive agent selected from a group consisting of ApoA-I Milano, recombinant ApoA-I Milano/phospholipid complexes, lipostabil, and combination thereof.

21-41(cancelled).